Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology
Thymic epithelial tumors (TETs) are rare and diverse cancers with distinctive immune features, limited prospective evidence, and few systemic options. Their association with autoimmunity, especially thymomas, complicates treatment decisions. This review examines molecular profiling and predictive biomarkers in TET and explores new treatment strategies. We highlight priorities for future trials, global registries, and real-world data to expand access to expert, multidisciplinary care, charting a path toward precision-guided, combination-based treatments.
Authors
- Surbhi Singhal (ORCID: https://orcid.org/0000-0003-4307-319X)
- Kavitha Ramchandran (ORCID: https://orcid.org/0000-0002-9033-819X)
- Jonathan W. Reiss
- Erica Pietroluongo (ORCID: https://orcid.org/0000-0003-2370-2139)
- Marina Chiara Garassino (ORCID: https://orcid.org/0000-0002-3821-5598)
- Jennifer A. Marks
- Jonathan W. Goldman
- J Remon
- M Aldea
- Anja C. Roden
- Christopher S. Nabel
- Mehmet Altan
- Chul Kim
- Rohan Maniar
- Heather Wakelee
- Patrick J. Loehrer
Institutions
- Mayo Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of California, Los Angeles (US)
- Palo Alto University (US)
- Georgetown University (US)
- Institut Gustave Roussy (FR)
- WinnMed (US)
- University of Chicago (US)
- University of Santa Monica (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber/Harvard Cancer Center (US)
- Global Cancer Institute (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- University of California, Davis (US)
- Stanford University (US)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2026-06-26
- DOI
- https://doi.org/10.1038/s41698-026-01574-z
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00